No information is available on the clinical use of ziconotide during breastfeeding. Ziconotide is usually not detectable or barely detectable in plasma after intrathecal administration, and because it is a peptide with a molecular weight of 2639 Daltons, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. If ziconotide is required by the mother, it is not a reason to discontinue breastfeeding. Breastfed infants should be monitored for sedation, which may result in respiratory depression or feeding problems.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Ziconotide
CAS Registry Number
107452-89-1
Drug Class
Breast Feeding
Lactation
Milk, Human
Analgesics, Non-Narcotic
Calcium Channel Blockers
Neuroprotective Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
